Is Your Technology Translatable and Fundable? How Experts Look at the Role of AI and Data
Bringing together mentors, entrepreneurs, and investors from the Wyss Institute and Harvard Innovation Labs, this panel will explore how experts decide whether a health or biotech innovation is truly ready to become a company. We’ll discuss what makes a technology translatable—scientifically, clinically, and commercially—and how your AI and data story shapes that judgment.
PANELISTS
Julien Pham – Physician, serial entrepreneur, and seed‑stage VC (Third Culture Capital), ex‑President/COO of a NASDAQ‑listed biotech (Genprex), co‑founder of RubiconMD, senior advisor at Harvard Innovation Labs. Focus on healthcare, digital health, AI/biotech, and equity.
Ajit Singh – CEO‑Partner at Flagship Pioneering, CEO of Harbinger Health, former CEO of BioImagene, ex–VC; teaches clinical technologies & entrepreneurship at Stanford. Deep experience in scaling, commercialization, and company building in medtech/oncology diagnostics.
David Duffy – Entrepreneurial scientist, former CTO/SVP R&D at Quanterix; long track record in bioanalytical platforms, diagnostics, and productization of deep tech. Now a Wyss Mentor focused on translation and commercialization of world‑class science.
In-person only. Panel discussion (3-4 PM).
Refreshments will be served during the networking session immediately after the talk (4:00-5:00 PM)
This Business Blueprint event is co-hosted by Harvard Innovation Labs and Wyss Institute at Harvard University.
